A profound med-tech breakthrough
Catherine Wood, CEO and CIO at ARK Investment Management (ARK), invests on the cutting edge of robotics, energy storage, next-generation internet and blockchain technology. However it is in the field of genomic sequencing that she tell us: “Something is happening that is more profound than I’ve ever experienced”.
Key points
- A revolutionary gene-editing technology has emerged that may potentially hold the cure for some diseases. The first human trials in the US are taking place this year in cases of paediatric blindness.
- Another technology that ARK is backing can turn a patient’s immune system against cancerous cells. It is yielding promising results in non-Hodgkin’s lymphoma.
Further insights
Nikko AM Australia is pleased to bring the ARK Investment Management strategies and capabilities to Australia. Click here to find out more
ARK Investment Management is a Nikko Asset Management strategic partner. This material is issued in Australia by Nikko AM Limited ABN 99 003 376 252, AFSL 237563.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Livewire Exclusive brings you exclusive content from a wide range of leading fund managers and investment professionals.
3 topics
2 contributors mentioned
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
The 7 zombie companies lurking on the ASX 300
Livewire Markets
Education
Warren Buffett’s 25 biggest mistakes – and 4 lessons they teach
Leithner & Company Ltd